Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 7;10(2):198.
doi: 10.3390/jcm10020198.

The Multifaceted Interplay between Atrial Fibrillation and Myocardial Infarction: A Review

Alban Belkouche  1 , Hermann Yao  1 , Alain Putot  2 , Frédéric Chagué  1 , Luc Rochette  3 , Nicolas Danchin  4 , Laurent Fauchier  5 , Marianne Zeller  3 , Yves Cottin  1
Affiliations
Review

The Multifaceted Interplay between Atrial Fibrillation and Myocardial Infarction: A Review

Alban Belkouche et al. J Clin Med. .

Abstract

This review was conducted to emphasize the complex interplay between atrial fibrillation (AF) and myocardial infraction (MI). In type 1 (T1) MI, AF is frequent and associated with excess mortality. Moreover, AF after hospital discharge for T1MI is not rare, suggesting the need to improve AF screening and to develop therapeutic strategies for AF recurrence. Additionally, AF is a common trigger for type 2 MI (T2MI), and recent data have shown that tachyarrhythmia or bradyarrhythmia could be a causal factor in, respectively, 13-47% or 2-7% of T2MI. In addition, AF is involved in T2MI pathogenesis as a result of severe anemia related to anticoagulants. AF is also an underestimated and frequent cause of coronary artery embolism (CE), as a situation at risk of myocardial infarction with non-obstructive coronary arteries. AF-causing CE is difficult to diagnose and requires specific management. Moreover, patients with both AF and chronic coronary syndromes represent a therapeutic challenge because the treatment of AF include anticoagulation, depending on the embolic risk, and ischemic heart disease management paradoxically includes antiplatelet therapy.

Keywords: atrial fibrillation; bleeding; chronic coronary syndrome; type 1 and type 2 myocardial infarction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Multifaceted interplay between atrial fibrillation and myocardial infarction.
See this image and copyright information in PMC

References

    1. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., Castella M., Christoph-Diener H., Heidbuchel H., Hendriks J., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016;37:2893–2962. doi: 10.1093/eurheartj/ehw210. - DOI - PubMed
    1. Thygesen K., Alpert J.S., Jaffe A.S., Chaitman B.R., Bax J.J., Morrow D.A., the Executive Group on behalf of the Joint European Society of Cardiology (ESC) American College of Cardiology (ACC) American Heart Association (AHA) World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction et al. Fourth Universal Definition of Myocardial Infarction (2018) Circulation. 2018;138:e618–e651. - PubMed
    1. Januzzi J.L., Sandoval Y. The Many Faces of Type 2 Myocardial Infarction. J. Am. Coll. Cardiol. 2017;70:1569–1572. doi: 10.1016/j.jacc.2017.07.784. - DOI - PubMed
    1. Chiang C.E., Naditch-Brûlé L., Murin J., Goethals M., Inoue H., O’Neill J., Silva-Cardoso J., Zharinov O., Gamra H., Alam S., et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fi-brillation in routine clinical practice insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ. Arrhythmia Electrophysiol. 2012;5:632–639. doi: 10.1161/CIRCEP.112.970749. - DOI - PubMed
    1. Ruff C.T., Giugliano R.P., Braunwald E., Hoffman E.B., Deenadayalu N., Ezekowitz M.D., Camm A.J., Weitz J.I., Lewis B.S., Parkhomenko A., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 2014;383:955–962. doi: 10.1016/s0140-6736(13)62343-0. - DOI - PubMed

LinkOut - more resources